# US 2021/0276949 A1 · Heterocyclic compound and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0276949 A1
- Document ID: US20210276949A1
- Status: Published application
- Kind: A1
- Application number: 17/239,191
- Filed: 2021-04-23
- Published: 2021-09-09
- Earliest claimed: 2019-01-31
- Assignees: Takeda Pharmaceutical Company Limited
- Applicants: Takeda Pharmaceutical Company Limited
- Inventors: Yasushi HATTORI; Yuhei MIYANOHANA; Yuichi KAJITA; Tatsuki KOIKE; Yasutaka HOASHI; Norihito TOKUNAGA; Alexander Martin PAWLICZEK; Tsuneo ODA; Tohru MIYAZAKI; Yoshiteru ITO; Kohei TAKEUCHI; Keisuke IMAMURA; Takahiro SUGIMOTO
- Web page: https://patentgrep.com/patent/US20210276949A1

## CPC

- C07D 207/14: Nitrogen atoms not forming part of a nitro radical
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/4025: not condensed and containing further heterocyclic rings, e.g. cromakalim
- A61K 31/422: not condensed and containing further heterocyclic rings
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 25/00: Drugs for disorders of the nervous system
- C07D 401/10: linked by a carbon chain containing aromatic rings
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 403/10: linked by a carbon chain containing aromatic rings
- C07D 403/14: containing three or more hetero rings
- C07D 407/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 407/08: linked by a carbon chain containing alicyclic rings
- C07D 413/10: linked by a carbon chain containing aromatic rings
- C07D 417/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 417/10: linked by a carbon chain containing aromatic rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

## Claims

### Claim 1

A compound represented by the formula (I):
wherein
R1 is an optionally substituted C1-6 alkyl group, an optionally substituted mono- or di-C1-6 alkylamino group, an optionally substituted C3-6 cycloalkyl group, or an optionally substituted 3- to 14-membered non-aromatic heterocyclic group;
R2 is a hydrogen atom, a fluorine atom, an optionally substituted C1-6 alkyl group, or an optionally substituted C3-6 cycloalkyl group;
R3 is an acyl group, an optionally substituted C1-6 alkyl group, an optionally substituted C3-6 cycloalkyl group, an optionally substituted C6-14 aryl group, an optionally substituted 3- to 14-membered non-aromatic heterocyclic group, or an optionally substituted 5- to 14-membered aromatic heterocyclic group; and
Ring A is an optionally further substituted C6-14 aromatic hydrocarbon ring, or an optionally further substituted 5- to 14-membered aromatic heterocycle,
or a salt thereof.

### Claim 2 (depends on 1)

The compound or salt according to claim 1, wherein
R1 is
(1) a C1-6 alkyl group,
(2) a mono- or di-C1-6 alkylamino group, or
(3) a C3-6 cycloalkyl group;
R2 is
(1) a hydrogen atom,
(2) a fluorine atom, or
(3) a C1-6 alkyl group;
R3 is
(1) a C1-6 alkyl-carbonyl group optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom,
(b) a hydroxy group, and
(c) a cyano group,
(2) a C1-6 alkoxy-carbonyl group,
(3) a C3-10 cycloalkyl-carbonyl group (the C3-10 cycloalkyl moiety of the C3-10 cycloalkyl-carbonyl group is optionally bridged) optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom,
(b) a hydroxy group,
(c) a cyano group, and
(d) a C1-6 alkyl group,
(4) a 3- to 14-membered non-aromatic heterocyclylcarbonyl group optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom,
(b) a hydroxy group, and
(c) a C1-6 alkyl group,
(5) a mono- or di-C1-6 alkyl-carbamoyl group,
(6) a N—C1-6 alkyl-N—C1-6 alkoxy-carbamoyl group, or
(7) a N—C1-6 alkyl-N′,N′-di-C1-6 alkylhydrazine-carbonyl group; and
Ring A is
(1) a benzene ring
further substituted by one substituent selected from
(a) a C6-14 aryl group optionally substituted by 1 to 3 substituents selected from
(i) a halogen atom,
(ii) an optionally halogenated C1-6 alkyl group, and
(iii) an optionally halogenated C1-6 alkoxy group, and
(b) a 5- to 14-membered aromatic heterocyclic group optionally substituted by 1 to 3 substituents selected from
(i) a C1-6 alkyl group optionally substituted by 1 to 3 substituents selected from a halogen atom and a hydroxy group,
(ii) a C1-6 alkoxy group,
(iii) a halogen atom, and
(iv) a C1-6 alkoxy-carbonyl group, and
optionally further substituted by 1 to 3 halogen atoms, or
(2) a 5- or 6-membered aromatic heterocycle further substituted by one C6-14 aryl group optionally substituted by 1 to 3 halogen atoms.

### Claim 3 (depends on 1)

The compound or salt according to claim 1, wherein
R1 is
(1) a C1-6 alkyl group,
(2) a mono- or di-C1-6 alkylamino group, or
(3) a C3-6 cycloalkyl group;
R2 is
(1) a hydrogen atom, or
(2) a fluorine atom;
R3 is (1) a C1-6 alkyl-carbonyl group optionally substituted by 1 to 3 hydroxy groups,
(2) a C3-10 cycloalkyl-carbonyl group (the C3-10 cycloalkyl moiety of the C3-10 cycloalkyl-carbonyl group is optionally bridged) optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom, and
(b) a hydroxy group,
(3) a 3- to 8-membered monocyclic non-aromatic heterocyclylcarbonyl group, or
(4) a mono- or di-C1-6 alkyl-carbamoyl group; and
Ring A is a benzene ring
further substituted by one C6-i4 aryl group optionally substituted by 1 to 3 substituents selected from
(i) a halogen atom, and
(ii) an optionally halogenated C1-6 alkyl group, and
optionally further substituted by 1 to 3 halogen atoms.

### Claim 4 (depends on 1)

The compound or salt according to claim 1, wherein
R1 is
(1) a C1-6 alkyl group, or
(2) a mono- or di-C1-6 alkylamino group;
R2 is
(1) a hydrogen atom, or
(2) a fluorine atom;
R3 is
(1) a C1-6 alkyl-carbonyl group optionally substituted by 1 to 3 hydroxy groups,
(2) a 3- to 8-membered monocyclic non-aromatic heterocyclylcarbonyl group, or
(3) a mono- or di-C1-6 alkyl-carbamoyl group; and
Ring A is a benzene ring
further substituted by one C6-14 aryl group optionally substituted by 1 to 3 substituents selected from
(i) a halogen atom, and
(ii) a C1-6 alkyl group, and
optionally further substituted by 1 to 3 halogen atoms.

### Claim at position 5

-7. (canceled)

### Claim 8 (depends on 1)

A medicament comprising the compound or salt according to claim 1.

### Claim 9 (depends on 8)

The medicament according to claim 8, which is an orexin type 2 receptor agonist.

### Claim at position 8

-11. (canceled)

### Claim 12 (depends on 1)

A method of activating an orexin type 2 receptor in a mammal, which comprises administering an effective amount of the compound or salt according to claim 1 to the mammal.

### Claim 13 (depends on 1)

A method for the prophylaxis or treatment of narcolepsy in a mammal, which comprises administering an effective amount of the compound or salt according to claim 1 to the mammal.

### Claim 14

(canceled)
